Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerhard Siemeister

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Organic & Biomolecular Chemistry|December 7, 2018
Alkoxyallene-based syntheses of preussin and its analogs and their cytotoxicityArndt Hausherr, Gerhard Siemeister, Hans-Ulrich Reissig
Chembiochem : a European Journal of Chemical Biology|April 8, 2009
Off-target decoding of a multitarget kinase inhibitor by chemical proteomicsEnrico Missner, Inke Bahr, Volker Badock, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|November 5, 2003
Differential regulation of in vivo angiogenesis by angiotensin II receptorsThomas Walther, Andreas Menrad, Hans-Dieter Orzechowski, et al.
Chemmedchem|November 30, 2006
Macrocyclic aminopyrimidines as multitarget CDK and VEGF-R inhibitors with potent antiproliferative activitiesUlrich Lücking, Gerhard Siemeister, Martina Schäfer, et al.
Cancer Research|August 8, 2019
Cellular and Genetic Determinants of the Sensitivity of Cancer to α-Particle IrradiationBrian D Yard, Priyanka Gopal, Kristina Bannik, et al.
Scientific Reports|December 8, 2019
Radiobiological effects of the alpha emitter Ra-223 on tumor cellsKristina Bannik, Balázs Madas, Marco Jarzombek, et al.
Translational Oncology|July 18, 2008
Tomoregulin internalization confers selective cytotoxicity of immunotoxins on prostate cancer cellsXiao-Yan Zhao, Hsiao-Lai Liu, Bing Liu, et al.
Molecular Cancer Therapeutics|July 24, 2012
BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral applicationGerhard Siemeister, Ulrich Lücking, Antje M Wengner, et al.
Scientific Reports|December 2, 2021
DNA repair inhibitors sensitize cells differently to high and low LET radiationKristina Bannik, Balázs Madas, Sabrina Jarke, et al.
ACS Chemical Biology|April 20, 2016
Conformational Adaption May Explain the Slow Dissociation Kinetics of Roniciclib (BAY 1000394), a Type I CDK Inhibitor with Kinetic Selectivity for CDK2 and CDK9Pelin Ayaz, Dorothee Andres, Dennis A Kwiatkowski, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Organic & Biomolecular Chemistry|December 7, 2018
Alkoxyallene-based syntheses of preussin and its analogs and their cytotoxicityArndt Hausherr, Gerhard Siemeister, Hans-Ulrich Reissig
Chembiochem : a European Journal of Chemical Biology|April 8, 2009
Off-target decoding of a multitarget kinase inhibitor by chemical proteomicsEnrico Missner, Inke Bahr, Volker Badock, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|November 5, 2003
Differential regulation of in vivo angiogenesis by angiotensin II receptorsThomas Walther, Andreas Menrad, Hans-Dieter Orzechowski, et al.
Chemmedchem|November 30, 2006
Macrocyclic aminopyrimidines as multitarget CDK and VEGF-R inhibitors with potent antiproliferative activitiesUlrich Lücking, Gerhard Siemeister, Martina Schäfer, et al.
Cancer Research|August 8, 2019
Cellular and Genetic Determinants of the Sensitivity of Cancer to α-Particle IrradiationBrian D Yard, Priyanka Gopal, Kristina Bannik, et al.
Scientific Reports|December 8, 2019
Radiobiological effects of the alpha emitter Ra-223 on tumor cellsKristina Bannik, Balázs Madas, Marco Jarzombek, et al.
Translational Oncology|July 18, 2008
Tomoregulin internalization confers selective cytotoxicity of immunotoxins on prostate cancer cellsXiao-Yan Zhao, Hsiao-Lai Liu, Bing Liu, et al.
Molecular Cancer Therapeutics|July 24, 2012
BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral applicationGerhard Siemeister, Ulrich Lücking, Antje M Wengner, et al.
Scientific Reports|December 2, 2021
DNA repair inhibitors sensitize cells differently to high and low LET radiationKristina Bannik, Balázs Madas, Sabrina Jarke, et al.
ACS Chemical Biology|April 20, 2016
Conformational Adaption May Explain the Slow Dissociation Kinetics of Roniciclib (BAY 1000394), a Type I CDK Inhibitor with Kinetic Selectivity for CDK2 and CDK9Pelin Ayaz, Dorothee Andres, Dennis A Kwiatkowski, et al.
Pageof 4